No significant differences in CD20 expression in DN2 B cells were observed between LOMG and EOMG; however, LOMG subjects exhibited significantly higher CD20 expression compared to MuSK-MG subjects, regardless of rituximab treatment status (Figure 6G). The gene discussed is MUSK; the disease is myasthenia gravis.